| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | Panobinostat | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.8 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.8 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |